| 2 |
Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on December 31, 2025, and approval of the allocation of the annual result as proposed by the Board of Directors. |
✓ For(592.550)
|
| 5 |
Acknowledgement and approval of the remuneration report. |
✓ For(592.550)
|
| 6 |
Release from liability to be granted to the (current and former) members of the Board of Directors, and the statutory auditor for the performance of their respective mandates during the financial year ended on December 31, 2025. |
✓ For(592.550)
|
| 7 |
Appointment of Mr. Henry Goossbruch as executive director |
✗ Against(592.550)
|
| 8 |
Appointment of Ms. Jane Griffiths as independent non-executive director |
✓ For(592.550)
|
| 9 |
Appointment of Ms. Dawn Svoronos as independent non-executive director |
✓ For(592.550)
|
| 10 |
Appointment of Dr. Neil Johnston as independent non-executive director |
✓ For(592.550)
|
| 11 |
Appointment of Mr. Devang Bhuva as non-executive director |
✗ Against(592.550)
|
| 12 |
Appointment of Dr. Paulo Fontoura as independent non-executive director |
✓ For(592.550)
|
| 13 |
Appointment of Mr. Gino Santini as independent non-executive director |
✓ For(592.550)
|
| 14 |
Re-appointment of statutory auditor and determination of statutory auditor’s remuneration |
✓ For(592.550)
|
| 15 |
Confirmation and re-appointment of the statutory auditor with respect to the "assurance" of the CSRD sustainability reporting and determination of statutory auditor’s remuneration. |
✓ For(592.550)
|
| 16 |
Remuneration of directors |
✓ For(592.550)
|
| 17 |
Change of name of the Company to "Lakefront Biotherapeutics" |
✓ For(592.550)
|
| 18 |
Amendment to the articles of association relating to the representation of the Company |
✓ For(592.550)
|
| 19 |
Authorization to the Board of Directors to acquire its own shares |
✓ For(592.550)
|
| 20 |
Renewal of the authorization to the Board of Directors to increase the share capital within the framework of the authorized capital by up to twenty percent (20%) of the share capital |
✓ For(592.550)
|
| 21 |
Proxy for coordination of the articles of association |
✓ For(592.550)
|
| 22 |
Authorization to the Board of Directors |
✓ For(592.550)
|
| 23 |
Proxy for the Crossroad Bank for Enterprises, counters for enterprises, registers of the enterprise court, administrative agencies and fiscal administrations |
✓ For(592.550)
|